Bionano Genomics COO reports 15,000-share option

Bionano Genomics, Inc. reports that Chief Operating Officer Mark Oldakowski beneficially owns a stock option giving the right to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share.

Rhea-AI Filing Summary

Bionano Genomics, Inc. reports that Chief Operating Officer Mark Oldakowski beneficially owns a stock option giving the right to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share. The option expires on August 2, 2036. According to the equity plan footnote, the shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case conditioned on the executive’s Continuous Service, as defined in the company’s 2018 plan. The position is reported as direct ownership.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OLDAKOWSKI MARK

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.

Key Figures

Option Underlying Shares: 15,000 shares Exercise Price: $1.12 per share Option Expiration: August 2, 2036 +1 more

4 metrics

Option Underlying Shares 15,000 shares Underlying Common Stock for COO stock option holding

Exercise Price $1.12 per share Strike price of COO stock option over 15,000 shares

Option Expiration August 2, 2036 Expiration date of reported stock option position

Vesting Schedule 50% on each of first and second anniversaries Vesting conditioned on Continuous Service under the 2018 Plan

Key Terms

Stock Option (Right to Buy), Continuous Service, underlying security, 2018 Plan

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Continuous Service financial

"subject to the Reporting Person's Continuous Service through each vesting date"

underlying security financial

"underlying_security_title: Common Stock; underlying_security_shares: 15000.0000"

2018 Plan financial

"Continuous Service (as defined in the Company's 2018 Plan)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did BNGO’s COO report in this Form 3 filing?

Bionano Genomics’ COO Mark Oldakowski reported beneficial ownership of a stock option to buy 15,000 shares of Common Stock at an exercise price of $1.12 per share, expiring on August 2, 2036.

What is the strike price and size of the COO’s option position in BNGO?

The COO’s disclosed derivative position is a stock option over 15,000 underlying shares of Common Stock with an exercise price of $1.12 per share. This position is reported as directly owned.

How does the BNGO COO’s stock option reported on Form 3 vest?

The option vests 50% of the total on each of the first and second anniversaries of the vesting commencement date. Each vesting tranche is subject to the executive’s Continuous Service as defined in the company’s 2018 Plan.

When does the BNGO COO’s reported stock option expire?

The reported stock option position for Bionano Genomics’ COO expires on August 2, 2036. After this expiration date, any unexercised portion of the 15,000-share option would no longer be exercisable under the stated terms.

Is the BNGO COO’s stock option held directly or indirectly?

The filing classifies the COO’s stock option as direct ownership. This means the 15,000-share option position over Bionano Genomics Common Stock is reported as directly held, rather than through a trust, fund, or other indirect entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:01 PM Accepted by SEC EDGAR 08/05/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

OLDAKOWSKI MARK

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	08/02/2036	Common Stock	15,000	$1.12	D

Explanation of Responses:

1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)